EP2217599A1 - Alpha-fluoralkyltetrabenazine und dihydrotetrabenazine als bilddarstellende mittel und sonden - Google Patents

Alpha-fluoralkyltetrabenazine und dihydrotetrabenazine als bilddarstellende mittel und sonden

Info

Publication number
EP2217599A1
EP2217599A1 EP08854913A EP08854913A EP2217599A1 EP 2217599 A1 EP2217599 A1 EP 2217599A1 EP 08854913 A EP08854913 A EP 08854913A EP 08854913 A EP08854913 A EP 08854913A EP 2217599 A1 EP2217599 A1 EP 2217599A1
Authority
EP
European Patent Office
Prior art keywords
alpha
compound
fluoroalkyl
compound according
aliphatic radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP08854913A
Other languages
English (en)
French (fr)
Inventor
Michael James Rishel
Bruce Fletcher Johnson
Kande Kankananamalage Dayarathna Amarasinghe
Sean Richard Dinn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Electric Co
Original Assignee
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/947,215 external-priority patent/US7902364B2/en
Priority claimed from US11/947,275 external-priority patent/US7910738B2/en
Application filed by General Electric Co filed Critical General Electric Co
Priority to EP20130155403 priority Critical patent/EP2594568A1/de
Publication of EP2217599A1 publication Critical patent/EP2217599A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • This invention relates to alpha-fluoroalkyl compounds related to tetrabenazine and dihydrotetrabenazine and intermediates useful in the preparation of such alpha-fluoroalkyl compounds.
  • tetrabenazine and structurally related compounds have been widely investigated, and a number of TBZ compounds and derivatives of tetrabenazine have shown promise in the treatment of a variety of conditions affecting human health.
  • dihydrotetrabenazine has been identified as an agent for the treatment of schizophrenia and other psychoses (See for example WO 2007017654 Al), and tetrabenazine has shown promise as an agent in the treatment of Huntington's disease (Neurology (2006), 66(3), 366-372).
  • the present invention provides both a new class of fluorinated tetrabenazine and dihydrotetrabenazine derivatives and fluorinated tetrabenazine and dihydrotetrabenazine analogs, and discloses efficient synthetic methodology which may be used to prepare such compounds in enantiomerically enriched or racemic forms.
  • the alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine compounds provided by the present invention are useful as PET imaging agents, probes for the development of PET imaging agents, and therapeutic agents.
  • the present invention provides novel synthetic intermediate compositions which may be used to prepare either or both enantiomers of the subject tetrabenazine and dihydrotetrabenazine derivatives and tetrabenazine and dihydrotetrabenazine analogs.
  • the present invention provides an alpha-fluoroalkyl tetrabenazine compound having structure I
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • the present invention provides a PET imaging agent comprising an alpha-fluoroalkyl tetrabenazine compound having structure I
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical comprising at least one fluorine- 18 atom
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • the present invention provides an alpha-fluoroalkyl dihydrotetrabenazine compound having structure IV
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 4 is hydrogen, a C 1 -C 10 aliphatic radical, a C 3 -C 10 cycloaliphatic radical, or a C 3 -C 10 aromatic radical.
  • the present invention provides a PET imaging agent comprising an alpha-fluoroalkyl dihydrotetrabenazine compound having structure IV
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical comprising at least one fluorine-18 atom
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 4 is hydrogen, a C 1 -C 10 aliphatic radical, a C 3 -C 10 cycloaliphatic radical, or a C 3 -C 10 aromatic radical.
  • solvent can refer to a single solvent or a mixture of solvents.
  • Approximating language may be applied to modify any quantitative representation that could permissibly vary without resulting in a change in the basic function to which it is related. Accordingly, a value modified by a term or terms, such as "about”, is not to be limited to the precise value specified. In some instances, the approximating language may correspond to the precision of an instrument for measuring the value.
  • aromatic radical refers to an array of atoms having a valence of at least one comprising at least one aromatic group.
  • the array of atoms having a valence of at least one comprising at least one aromatic group may include heteroatoms such as nitrogen, sulfur, selenium, silicon and oxygen, or may be composed exclusively of carbon and hydrogen.
  • aromatic radical includes but is not limited to phenyl, pyridyl, furanyl, thienyl, naphthyl, phenylene, and biphenyl radicals.
  • the aromatic radical contains at least one aromatic group.
  • the aromatic radical may also include nonaromatic components.
  • a benzyl group is an aromatic radical which comprises a phenyl ring (the aromatic group) and a methylene group (the nonaromatic component).
  • a tetrahydronaphthyl radical is an aromatic radical comprising an aromatic group (C O H 3 ) fused to a nonaromatic component -(CH 2 ) 4 -.
  • aromatic radical is defined herein to encompass a wide range of functional groups such as alkyl groups, alkenyl groups, alkynyl groups, haloalkyl groups, haloaromatic groups, conjugated dienyl groups, alcohol groups, ether groups, aldehyde groups, ketone groups, carboxylic acid groups, acyl groups (for example carboxylic acid derivatives such as esters and amides), amine groups, nitro groups, and the like.
  • the 4-methylphenyl radical is a C 7 aromatic radical comprising a methyl group, the methyl group being a functional group which is an alkyl group.
  • the 2-nitrophenyl group is a C 6 aromatic radical comprising a nitro group, the nitro group being a functional group.
  • Aromatic radicals include halogenated aromatic radicals such as 4- trifluoromethylphenyl, hexafluoroisopropylidenebis(4-phen-1-yloxy) (i.e., -OPhC(CF 3 ) 2 PhO- ), 4-chloromethylphen-1-yl, 3-trifluorovinyl-2-thienyl, 3-trichloromethylphen-1-yl (i.e., 3- CCl 3 Ph-), 4-(3-bromoprop-1-yl)phen-1-yl (i.e., 4-BrCH 2 CH 2 CH 2 Ph-), and the like.
  • halogenated aromatic radicals such as 4- trifluoromethylphenyl, hexafluoroisopropylidenebis(4-phen-1-yloxy) (i.e., -OPhC(CF 3 ) 2 PhO- ), 4-chloromethylphen-1-yl, 3-trifluorovinyl-2-thienyl,
  • aromatic radicals include 4-allyloxyphen-1-oxy, 4-aminophen-1-yl (i.e., 4- H 2 NPh-), 3-aminocarbonylphen-1-yl (i.e., NH 2 COPh-), 4-benzoylphen-1-yl, dicyanomethylidenebis(4-phen-1-yloxy) (i.e., -OPhC(CN) 2 PhO-), 3-methylphen-1-yl, methylenebis(4-phen-1-yloxy) (i.e., -OPhCH 2 PhO-), 2-ethylphen-1-yl, phenylethenyl, 3- formyl-2-thienyl, 2-hexyl-5-furanyl, hexamethylene-1,6-bis(4-phen-1-yloxy) (i.e., -OPh(CH 2 ) 6 PhO-), 4-hydroxymethylphen-1-yl (i.e., 4-HOCH 2 Ph-), 4-mer
  • a C 3 - C 10 aromatic radical includes aromatic radicals containing at least three but no more than 10 carbon atoms.
  • the aromatic radical 1- imidazolyl (C 3 H 2 N 2 -) represents a C 3 aromatic radical.
  • the benzyl radical (C 7 H 7 -) represents a C 7 aromatic radical.
  • cycloaliphatic radical refers to a radical having a valence of at least one, and comprising an array of atoms which is cyclic but which is not aromatic. As defined herein a “cycloaliphatic radical” does not contain an aromatic group.
  • a "cycloaliphatic radical” may comprise one or more noncyclic components.
  • a cyclohexylmethyl group (C 6 H 11 CH 2 -) is a cycloaliphatic radical which comprises a cyclohexyl ring (the array of atoms which is cyclic but which is not aromatic) and a methylene group (the noncyclic component).
  • the cycloaliphatic radical may include heteroatoms such as nitrogen, sulfur, selenium, silicon and oxygen, or may be composed exclusively of carbon and hydrogen.
  • cycloaliphatic radical is defined herein to encompass a wide range of functional groups such as alkyl groups, alkenyl groups, alkynyl groups, haloalkyl groups, conjugated dienyl groups, alcohol groups, ether groups, aldehyde groups, ketone groups, carboxylic acid groups, acyl groups (for example carboxylic acid derivatives such as esters and amides), amine groups, nitro groups, and the like.
  • the 4-methylcyclopent- 1-yl radical is a C 6 cycloaliphatic radical comprising a methyl group, the methyl group being a functional group which is an alkyl group.
  • the 2-nitrocyclobut-1-yl radical is a C 4 cycloaliphatic radical comprising a nitro group, the nitro group being a functional group.
  • a cycloaliphatic radical may comprise one or more halogen atoms which may be the same or different. Halogen atoms include, for example; fluorine, chlorine, bromine, and iodine.
  • Cycloaliphatic radicals comprising one or more halogen atoms include 2- trifluoromethylcyclohex- 1-yl, 4-bromodifluoromethylcyclooct- 1-yl, 2- chlorodifluoromethylcyclohex-1-yl, hexafluoroisopropylidene-2,2-bis (cyclohex-4-yl) (i.e., - C O H 1O C(CF S ) 2 C O H 1O -), 2-chloromethylcyclohex-1-yl, 3- difluoromethylenecyclohex-1-yl, A- trichloromethylcyclohex- 1 -yloxy, 4-bromodichloromethylcyclohex- 1 -ylthio, 2- bromoethylcyclopent-1-yl, 2-bromopropylcyclohex-l -yloxy (e.g., CH 3 CHBrCH 2 CoH 10 O-), and the like.
  • cycloaliphatic radicals include 4-allyloxycyclohex-1-yl, A- aminocyclohex-1-yl (i.e., H 2 NC O H 1O -), 4-aminocarbonylcyclopent-1-yl (i.e., NH 2 COCsHg-), 4-acetyloxycyclohex-1-yl, 2,2-dicyanoisopropylidenebis(cyclohex-4-yloxy) (i.e., OC O H 1O C(CN) 2 C O H 1O O-), 3-methylcyclohex-1-yl, methylenebis(cyclohex-4-yloxy) (i.e., - OC 6 H 1O CH 2 C 6 H 1O O-), 1-ethylcyclobut-1-yl, cyclopropylethenyl, 3-formyl-2- terahydrofuranyl, 2-hexyl-5-tetrahydrofuranyl, hexam
  • a C 3 - C 10 cycloaliphatic radical includes cycloaliphatic radicals containing at least three but no more than 10 carbon atoms.
  • the cycloaliphatic radical 2-tetrahydrofuranyl (C 4 H 7 O-) represents a C 4 cycloaliphatic radical.
  • the cyclohexylmethyl radical (C 6 H 11 CH 2 -) represents a C 7 cycloaliphatic radical.
  • aliphatic radical refers to an organic radical having a valence of at least one consisting of a linear or branched array of atoms which is not cyclic. Aliphatic radicals are defined to comprise at least one carbon atom.
  • the array of atoms comprising the aliphatic radical may include heteroatoms such as nitrogen, sulfur, silicon, selenium and oxygen or may be composed exclusively of carbon and hydrogen.
  • the term "aliphatic radical" is defined herein to encompass, as part of the "linear or branched array of atoms which is not cyclic" a wide range of functional groups such as alkyl groups, alkenyl groups, alkynyl groups, haloalkyl groups, conjugated dienyl groups, alcohol groups, ether groups, aldehyde groups, ketone groups, carboxylic acid groups, acyl groups (for example carboxylic acid derivatives such as esters and amides), amine groups, nitro groups, and the like.
  • the 4-methylpent-1-yl radical is a C 6 aliphatic radical comprising a methyl group, the methyl group being a functional group which is an alkyl group.
  • the A- nitrobut-1-yl group is a C 4 aliphatic radical comprising a nitro group, the nitro group being a functional group.
  • An aliphatic radical may be a haloalkyl group which comprises one or more halogen atoms which may be the same or different. Halogen atoms include, for example; fluorine, chlorine, bromine, and iodine.
  • Aliphatic radicals comprising one or more halogen atoms include the alkyl halides trifluoromethyl, bromodifluoromethyl, chlorodifluoromethyl, hexafluoroisopropylidene, chloromethyl, difluorovinylidene, trichloromethyl, bromodichloromethyl, bromoethyl, 2-bromotrimethylene (e.g., CH 2 CHBrCH 2 -), and the like.
  • aliphatic radicals include allyl, aminocarbonyl (i.e., -CONH 2 ), carbonyl, 2,2-dicyanoisopropylidene (i.e., -CH 2 C(CN) 2 CH 2 -), methyl (i.e., -CH 3 ), methylene (i.e., -CH 2 -), ethyl, ethylene, formyl (i.e. ,-CHO), hexyl, hexamethylene, hydroxymethyl (i.e.
  • a C 1 - C 10 aliphatic radical contains at least one but no more than 10 carbon atoms.
  • a methyl group i.e., CH 3 -
  • a decyl group i.e., CH 3 (CH 2 )g-
  • CH 3 (CH 2 )g- is an example of a C 10 aliphatic radical.
  • the present invention provides an alpha-fluoro alkyl tetrabenazine compound having structure I
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • R 1 is suitably selected from C 1-6 fluoroalkyl, C 1-6 fluoroalkoxy ⁇ i- ⁇ alkyl), C 1-6 fluorohaloalkyl, C 1-6 fluorohydroxyalkyl, and C 1-6 fluoroalkylcarbony ⁇ C 1-6 alkyl);
  • R 2 and R 3 are each suitably independently selected from hydrogen, C 1-6 alkyi and C 1-6 alkoxy.
  • R 4 in the compound of formula (IV) is suitably selected from hydrogen, C 1-6 alkylcarbonyl, aminocarbonyl, and (C 1-6 alky ⁇ aminocarbonyl.
  • R 4 is hydrogen.
  • R 4 is a C 1 -C 10 aliphatic radical, a C 3 -C 10 cycloaliphatic radical, or a C 3 -C 10 aromatic radical.
  • the present invention provides an alpha-fluoroalkyl dihydrotetrabenazine compound having structure IV
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 4 is hydrogen, a C 1 -C 10 aliphatic radical, a C 3 -C 10 cycloaliphatic radical, or a C 3 -C 10 aromatic radical.
  • alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine compounds I and IV provided by the present invention are shown herein to possess a high affinity for Type 2 Vesicular
  • VMAT-2 Monoamine Transporters
  • the present invention provides radiolabeled alpha-fluoroalkyl tetrabenzine compounds falling within the scope of generic structure I comprising a fluorine- 18 atom.
  • the present invention provides radiolabeled alpha- fluoroalkyl dihydrotetrabenazine compounds falling within the scope of generic structure IV comprising a fluorine- 18 atom.
  • Fluorine- 18 labeled alpha-fluoroalkyl tetrabenzine compounds I and alpha-fluoroalkyl dihydrotetrabenzine compounds IV are suitable for use as imaging agents for positron emission tomography (PET) screening of human patients, for example for pathological conditions related to diabetes. Positron emission tomography has become a medical imaging technique of critical importance to human health.
  • the present invention provides alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine compounds falling within the scope of either generic structure I or IV and comprising a fluorine- 19 atom, a stable isotope of fluorine.
  • the alpha-fluoroalkyl compounds comprising a fluorine- 19 atom are useful in binding studies which allow the identification of those alpha-fluoroalkyl compounds possessing optimal affinity for a target biomarker, for example VMAT-2.
  • a substantial binding affinity of a given fluorine- 19 containing alpha-fluoroalkyl tetrabenzine or dihydrotetrabenazine compound for a target biomarker such as VMAT-2 is a reliable predictor of utility in PET imaging of the corresponding fluorine- 18 containing alpha-fluoroalkyl compound.
  • alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine compounds I and IV show substantial binding affinity for the biomarker VMAT-2.
  • alpha- fluoroalkyl tetrabenazine and dihydrotetrabenazine compounds provided by the present invention are useful in the study and treatment of a variety of human and animal diseases as imaging agents, as probes for the development of imaging agents, and as therapeutic agents.
  • Alpha-fluoroalkyl tetrabenazine compounds having structure I are illustrated in Table 1 below.
  • structure I depicts an alpha-fluoroalkyl tetrabenazine compound in which no absolute or relative stereochemistry is shown.
  • structure I is intended to represent a genus of alpha-fluoroalkyl tetrabenazine compounds which includes the racemic compound Ia (Table 1) having both the R configuration and S configuration at ring positions-3 and 12.
  • structure I represents alpha-fluoroalkyl tetrabenazine compound Ib (Table 1) having the R configuration (absolute stereochemistry) at ring positions-3 and 12.
  • structure I represents compound Id (Table 1) having absolute stereochemistry opposite that of compound Ib.
  • the present invention provides an alpha-fluoroalkyl tetrabenzine compound having structure I which may be a racemic mixture (e.g. compound Ia (Table 1), a single enantiomer (e.g. compound Ib (Table 1), or a composition enantiomerically enriched in a single principal component enantiomer.
  • Entries 2a- 2c in Table 2 below illustrate alpha-fluoroalkyl tetrabenazine compounds I comprising a principal component enantiomer and at least one minor component enantiomer.
  • the alpha-fluoroalkyl tetrabenazine compositions comprise a principal component enantiomer (the structures appearing under the title heading "Structure of Principal Component Enantiomer") and a "Minor Component Enantiomer".
  • the mole percentage of the principal component enantiomer is given as "mole%” and refers to the mole percentage of the principal component enantiomer having the structure shown relative to the amounts of all other alpha- fluoroalkyl tetrabenazine components in the composition.
  • an alpha-fluoroalkyl tetrabenazine is any compound falling within the scope of generic structure I.
  • Entry 2a represents an alpha-fluoroalkyl tetrabenazine composition comprising 95 mole% of the R, R principal component enantiomer shown and a lesser amount of the S, S minor component enantiomer.
  • Entry 2c represents an alpha-fluoroalkyl tetrabenazine composition comprising 88 mole percent of the S, S principal component enantiomer having the structure shown and a lesser amount of the R, R minor component enantiomer.
  • the tetrabenazine and dihydrotetrabenazine compositions provided by the present invention may comprise a principal component enantiomer, a minor component enantiomer, and additional diastereomeric tetrabenazine or dihydrotetrabenazine components.
  • the present invention provides an alpha-fluoroalkyl tetrabenazine composition comprising a principal component enantiomer and related diastereomers.
  • the present invention provides an alpha- fluoroalkyl tetrabenazine composition having no principal component enantiomer and which is a diastereomeric mixture.
  • the present invention provides an alpha-fluoroalkyl tetrabenazine compound represented by structure I which is enantiomerically enriched and is comprised of at least 95 mole percent (mole %) of an enantiomer having the R configuration at ring position- 12.
  • the present invention provides an alpha-fluoroalkyl tetrabenazine compound represented by structure I which is enantiomerically enriched and is comprised of at least 95 mole percent (mole %) of an enantiomer having the R configuration at ring position-3.
  • the present invention provides an alpha-fluoroalkyl tetrabenazine compound having structure I in which the fluorinated aliphatic radical at ring position-3 (-R 1 ) has a syn-configuration relative to the hydrogen at ring position- 12.
  • the principal component enantiomers of Entries 2a- 2c of Table 2 illustrate alpha-fluoroalkyl tetrabenazine compounds in which the fluorinated aliphatic moiety at ring position-3 (-R 1 ) has a syn-configuration relative to the hydrogen at ring position- 12.
  • the present invention provides an enantiomeric ally enriched alpha- fluoroalkyl tetrabenazine compound comprising a principal component enantiomer having structure II
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • the present invention provides an enantiomeric ally enriched alpha- fluoroalkyl tetrabenazine compound comprising at least 80 mole percent of an enantiomer having structure II, for example the composition comprising the compound of Entry 3a (Table 3) wherein the R, R enantiomer shown represents at least 80 mole percent relative to the amounts of all other alpha-fluoroalkyl tetrabenazine components in the composition.
  • the present invention provides an enantiomerically enriched alpha-fluoroalkyl tetrabenazine compound which is comprised of at least 95 mole % of an enantiomer having structure II, for example an alpha-fluoroalkyl tetrabenazine composition comprising the compound of Entry 3b (Table 3) wherein the R, R enantiomer shown represents at least 95 mole percent relative to the amounts of all other alpha-fluoroalkyl tetrabenazine components in the composition.
  • the present invention provides an enantiomerically enriched alpha- fluoroalkyl tetrabenazine compound comprising a principal component enantiomer having structure II wherein R 1 is a Cs-C 10 fluorinated aliphatic radical; and R 2 and R 3 are methoxy groups and which are illustrated in Table 4 below.
  • Table 4 Principal Component Enantiomers Having Structure II Wherein R 1 Is A Cs-C 10 Fluorinated Aliphatic Radical And R 2 And R 3 Are Methoxy Groups
  • the present invention provides an enantiomeric ally enriched alpha- fluoroalkyl compound comprising a principal component enantiomer having structure III
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • the present invention provides an enantiomeric ally enriched alpha- fluoroalkyl tetrabenazine compound comprising at least 80 mole percent of an enantiomer having structure III, for example an alpha-fluoroalkyl tetrabenazine composition comprising the compound of Entry 5a (Table 5) wherein the S, S enantiomer shown represents at least 80 mole percent relative to the amounts of all other alpha-fluoroalkyl tetrabenazine components in the composition.
  • the present invention provides an enantiomerically enriched alpha-fluoroalkyl tetrabenazine compound comprising at least 95 mole percent of an enantiomer having structure III, for example an alpha-fluoroalkyl tetrabenazine composition comprising the compound of Entry 5b (Table 5) wherein the S, S enantiomer shown represents at least 95 mole percent relative to the amounts of all other alpha-fluoroalkyl tetrabenazine components in the composition.
  • the present invention provides an enantiomerically enriched alpha- fluoroalkyl compound comprising a principal component enantiomer having structure III wherein R 1 is a Cs-C 10 fluorinated aliphatic radical; and R 2 and R 3 are methoxy groups, and which are illustrated in Table 6 below.
  • novel alpha-fluoroalkyl tetrabenazine compounds I novel alpha-fluoroalkyl dihydrotetrabenazine compounds IV, and in certain embodiments, mixtures thereof.
  • Alpha-fluoroalkyl dihydrotetrabenazine compounds having structure IV are illustrated in Tables 7 and 7a below.
  • Structure IV represents a genus of alpha-fluoroalkyl dihydrotetrabenazine compounds which includes the racemic compound 7a (Table 7) and compound 7aa (Table 7a) having both the R configuration and S configuration at ring positions-2, 3 and 12.
  • structure IV represents alpha-fluoroalkyl dihydrotetrabenazine compound 7b (Table 7) or compound 7ab (Table 7a) having the R configuration (absolute stereochemistry) at ring positions-2, 3 and 12.
  • structure IV represents compound 7f (Table 7) having absolute stereochemistry opposite that of compound 7b or compound 7af (Table 7a) having absolute stereochemistry oppostite that of compound 7ab.
  • alpha-fluoroalkyl dihydrotetrabenazine compounds shown in Table 7 and Table 7a herein are illustrative of dihydrotetrabenazine (DTBZ) derivatives falling within the scope of generic structure IV.
  • DTBZ dihydrotetrabenazine
  • alpha-fluoroalkyl dihydrotetrabenazine compounds 7d, 7e, 7ad and 7ae represent diastereomeric mixtures.
  • the present invention provides an alpha-fluoroalkyl dihydrotetrabenzine compound having structure IV which may be a racemic mixture (e.g. compound 7a (Table 7), a single enantiomer (e.g. compound 7b (Table 7), or a composition enantiomerically enriched in a single principal component enantiomer.
  • Entries 8a-8c in Table 8 below illustrate alpha-fluoroalkyl dihydrotetrabenazine compounds IV comprising a principal component enantiomer and at least one minor component enantiomer.
  • the alpha-fluoroalkyl dihydrotetrabenazine compositions comprise a principal component enantiomer and a minor component enantiomer.
  • the mole percentage of the principal component enantiomer is given as "mole%" and refers to the mole percentage of the principal component enantiomer having the structure shown relative to the amounts of all other alpha- fluoroalkyl dihydrotetrabenazine components in the composition.
  • an alpha-fluoroalkyl dihydrotetrabenazine is any compound falling within the scope of generic structure IV.
  • Entries 8a and 8d represent an alpha-fluoroalkyl dihydrotetrabenazine composition comprising 98 mole% of the R, R, R principal component enantiomer shown and a lesser amount of the S, S, S minor component enantiomer.
  • Entries 8c and 8f represent an alpha-fluoroalkyl dihydrotetrabenazine composition comprising 88 mole percent of the S, S, S principal component enantiomer having the structure shown and a lesser amount of the R, R, R minor component enantiomer.
  • Entries 8b and 8e represent a pair of diastereomers comprising the R, S, R-enantiomer shown as the principal component enantiomer, and a minor component S, S, S- enantiomer.
  • the present invention provides an alpha-fluoroalkyl dihydrotetrabenazine compound represented by structure IV which is enantiomerically enriched and is comprised of at least 95 mole percent (mole %) of an enantiomer having the R configuration at ring position- 12.
  • the present invention provides an alpha-fluoroalkyl dihydrotetrabenazine compound represented by structure IV which is enantiomerically enriched and is comprised of at least 95 mole percent (mole %) of an enantiomer having the R configuration at ring position-3.
  • the present invention provides an alpha-fluoroalkyl dihydrotetrabenazine compound having structure IV in which the fluorinated aliphatic radical at ring position-3 (- R 1 ) has a syn-configuration relative to the hydrogen at ring position- 12.
  • the principal component enantiomers of Entries 8a-8f of Table 8 illustrate alpha-fluoroalkyl dihydrotetrabenazine compounds in which the fluorinated aliphatic moiety at ring position-3 (-R 1 ) has a syn-configuration relative to the hydrogen at ring position- 12.
  • the present invention provides an enantiomeric ally enriched alpha- fluoroalkyl dihydrotetrabenazine compound comprising a principal component enantiomer having structure V
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 4 is hydrogen, a C 1 -C 10 aliphatic radical, a C 3 -C 10 cycloaliphatic radical, or a C 3 -C 10 aromatic radical.
  • the present invention provides an enantiomeric ally enriched alpha- fluoroalkyl dihydrotetrabenazine compound comprising at least 80 mole percent of an enantiomer having structure V, for example the composition comprising the compound of Entries 9a and 9d (Table 9) wherein the R, R, R enantiomer shown represents at least 80 mole percent relative to the amounts of all other alpha-fluoroalkyl dihydrotetrabenazine components in the composition.
  • the present invention provides an enantiomerically enriched alpha-fluoroalkyl dihydrotetrabenazine compound which is comprised of at least 95 mole % of an enantiomer having structure V, for example an alpha-fluoroalkyl dihydrotetrabenazine composition comprising the compound of Entries 9b and 9e (Table 9 wherein the R, R, R enantiomer shown represents at least 95 mole percent relative to the amounts of all other alpha-fluoroalkyl dihydrotetrabenazine components in the composition.
  • the present invention provides an enantiomerically enriched alpha- fluoroalkyl dihydrotetrabenazine compound comprising a principal component enantiomer having structure V wherein R 1 is a Cs-C 10 fluorinated aliphatic radical; and R 2 and R 3 are methoxy groups and which are illustrated in Table 10 below.
  • the present invention provides an enantiomeric ally enriched alpha- fluoroalkyl dihydrotetrabenazine compound comprising a principal component enantiomer having structure VI
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 4 is hydrogen, a C 1 -C 10 aliphatic radical, a C 3 -C 10 cycloaliphatic radical, or a C 3 -C 10 aromatic radical.
  • the present invention provides an enantiomeric ally enriched alpha- fluoroalkyl dihydrotetrabenazine compound comprising at least 80 mole percent of an enantiomer having structure VI, for example an alpha-fluoroalkyl dihydrotetrabenazine composition comprising the compound of Entry 11a or Hd (Table 11) wherein the S, S, S enantiomer shown represents at least 80 mole percent relative to the amounts of all other alpha-fluoroalkyl dihydrotetrabenazine components in the composition.
  • the present invention provides an enantiomerically enriched alpha-fluoroalkyl dihydrotetrabenazine compound comprising at least 95 mole percent of an enantiomer having structure VI, for example an alpha-fluoroalkyl dihydrotetrabenazine composition comprising the compound of Entry l ib or l ie (Table 11) wherein the S, S, S enantiomer shown represents at least 95 mole percent relative to the amounts of all other alpha-fluoroalkyl dihydrotetrabenazine components in the composition.
  • the present invention provides an enantiomerically enriched alpha- fluoroalkyl dihydrotetrabenazine compound comprising a principal component enantiomer having structure VI wherein R 1 is a Cs-C 10 fluorinated aliphatic radical; and R 2 and R 3 are methoxy groups, and which are illustrated in Table 12 below.
  • alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine compounds provided by the present invention are at times herein referred to collectively as "alpha-fluoroalkyl compounds".
  • alpha-fluoroalkyl refers to the group R 1 of structures I- VI which represents a C 1 -C 10 aliphatic radical and is not restricted to the ordinary meaning of the term "alkyl”.
  • alpha- fluoroalkyl tetrabenazine is used extensively herein for convenience and means a tetrabenazine compound comprising a C 1 -C 10 fluorinated aliphatic radical at ring position-3.
  • alpha-fluoroalkyl dihydrotetrabenazine refers to a dihydrotetrabenazine compound comprising a C 1 -C 10 fluorinated aliphatic radical at ring position-3.
  • the fluorine- 18 labeled compounds of formula (I), (II), (III), (IV), (V), and (VI) have use as PET imaging agents for the VMAT-2 biomarker. Therefore, according to a further aspect of the invention, there is provided a method for detection of VMAT-2 in a subject, comprising : (i) administration of a fluorine- 18 labeled compound of formula (I), (II), (III), (IV), (V), or (VI) as defined above, or a salt thereof to said subject;
  • Such a method provides information and data having utility in the diagnosis and clinical research of VMAT-2 related disorders, for example by providing a method for determining beta cell mass.
  • the subject is a mammal, most suitably a human who has or is suspected of having a VMAT-2 related disorder.
  • VMAT-2 in healthy human volunteers for example for clinical research purposes.
  • the imaging of VMAT-2 may be carried out quantitatively such that the amount or change in amount of
  • VMAT-2 may be determined so as to diagnose or track progress of a disease. Alternatively the imaging of VMAT-2 may be used to locate VMAT-2.
  • VMAT-2 related disorder means a VMAT-2 related disease in the brain such as Huntington's, Parkinson's, or schizophrenia, or of the pancreas such as beta cell associated disorder including an insulinoma or other neuroendocrine tumour, or diabetes (for example type 1 diabetes, type 2 diabetes, or preclinical type 1 diabetes).
  • the VMAT-2 related disorder is diabetes.
  • the VMAT-2 related disorder is schizophrenia.
  • a fluorine- 18 labeled compound of formula (I), (II), (III), (IV), (V), or (VI) or a salt thereof in the manufacture of a radiopharmaceutical for the in vivo PET diagnosis or imaging of a VMAT-2 related disorder.
  • a fluorine- 18 labeled compound of formula (I), (II), (III), (IV), (V), or (VI) or a salt thereof for use in the in vivo PET diagnosis or imaging of a VMAT-2 related disorder.
  • a method for the in vivo diagnosis or imaging of a VMAT-2 related disorder in a subject comprising administration of a fluorine- 18 labeled compound of formula (I), (II), (III), (IV), (V), or (VI) or a salt thereof and detecting the uptake of said compound by an in vivo PET imaging technique.
  • the method is especially preferred for the in vivo diagnosis or imaging of diabetes.
  • the method comprises detecting the uptake of a fluorine- 18 labeled compound of formula (I), (II), (III), (IV), (V), or (VI) or a salt thereof by an in vivo PET imaging technique in a subject, preferably a human to whom said compound has been pre-administered.
  • the invention further provides a method of monitoring the effect of treatment of a subject, preferably a human with a drug to combat a VMAT-2 related disorder, said method comprising administering to said subject a fluorine- 18 labeled compound of formula (I), (II), (III), (IV), (V), or (VI) or a salt thereof and detecting the uptake of said compound by an in vivo PET imaging technique, said administration and detection optionally but preferably being effected repeatedly, e.g. before, during and after treatment with said drug.
  • a compound of formula (I), (II), (III), (IV), (V), or (VI) or a salt thereof is preferably administered for in vivo use in a pharmaceutical formulation comprising said compound and a pharmaceutically acceptable excipient, such formulations thus form a further aspect of the invention.
  • a "pharmaceutical formulation” is defined in the present invention as a formulation comprising an effective amount of a compound of formula (I), (II), (III), (IV), (V), or (VI) or a salt thereof in a form suitable for administration to a mammal, suitably a human.
  • the "pharmaceutically acceptable excipient” is a suitably a fluid, especially a liquid, in which the compound of formula (I), (II), (III), (IV), (V), or (VI) or a salt thereof can be suspended or dissolved, such that the formulation is physiologically tolerable, ie. can be administered to the mammalian body without toxicity or undue discomfort.
  • the pharmaceutically acceptable excipient is suitably an injectable carrier liquid such as sterile, pyrogen-free water for injection; an aqueous solution such as saline (which may advantageously be balanced so that the final formulation for injection is isotonic); an aqueous solution of one or more tonicity-adjusting substances (for example, salts of plasma cations with biocompatible counterions), sugars (for example, glucose or sucrose), sugar alcohols (for example, sorbitol or mannitol), glycols (for example, glycerol), or other non-ionic polyol materials (for example, polyethylene glycols, propylene glycols and the like).
  • injectable carrier liquid such as sterile, pyrogen-free water for injection
  • an aqueous solution such as saline (which may advantageously be balanced so that the final formulation for injection is isotonic)
  • an aqueous solution of one or more tonicity-adjusting substances for example, salts of plasma cations with biocompatible counter
  • the pharmaceutically acceptable excipient is pyrogen-free water for injection or isotonic saline.
  • the pharmaceutical formulation may optionally contain additional excipients such as an antimicrobial preservative, pH-adjusting agent, filler, stabiliser or osmolality adjusting agent.
  • an antimicrobial preservative is meant an agent which inhibits the growth of potentially harmful micro-organisms such as bacteria, yeasts or moulds.
  • the antimicrobial preservative may also exhibit some bactericidal properties, depending on the dosage employed.
  • the main role of the antimicrobial preservative(s) of the present invention is to inhibit the growth of any such micro-organism in the pharmaceutical formulation.
  • the antimicrobial preservative may, however, also optionally be used to inhibit the growth of potentially harmful micro-organisms in one or more components of kits used to prepare said pharmaceutical formulation prior to administration.
  • Suitable antimicrobial preservative(s) include: the parabens, ie. methyl, ethyl, propyl or butyl paraben or mixtures thereof; benzyl alcohol; phenol; cresol; cetrimide and thiomersal.
  • Preferred antimicrobial preservative(s) are the parabens.
  • pH-adjusting agent means a compound or mixture of compounds useful to ensure that the pH of the pharmaceutical formulation is within acceptable limits (approximately pH 4.0 to 10.5) for human or mammalian administration. Suitable such pH-adjusting agents include pharmaceutically acceptable buffers, such as tricine, phosphate or TRIS [ie. tris(hydroxymethyl)aminomethane], and pharmaceutically acceptable bases such as sodium carbonate, sodium bicarbonate or mixtures thereof.
  • buffers such as tricine, phosphate or TRIS [ie. tris(hydroxymethyl)aminomethane]
  • pharmaceutically acceptable bases such as sodium carbonate, sodium bicarbonate or mixtures thereof.
  • the pH adjusting agent may optionally be provided in a separate vial or container, so that the user of the kit can adjust the pH as part of a multi-step procedure.
  • filler is meant a pharmaceutically acceptable bulking agent which may facilitate material handling during production and lyophilisation.
  • suitable fillers include inorganic salts such as sodium chloride, and water soluble sugars or sugar alcohols such as sucrose, maltose, mannitol or trehalose.
  • the pharmaceutical formulations of the invention are typically supplied in suitable vials or vessels which comprise a sealed container which permits maintenance of sterile integrity and/or radioactive safety, plus optionally an inert headspace gas (eg. nitrogen or argon), whilst permitting addition and withdrawal of solutions by syringe or cannula.
  • a sealed container which permits maintenance of sterile integrity and/or radioactive safety, plus optionally an inert headspace gas (eg. nitrogen or argon), whilst permitting addition and withdrawal of solutions by syringe or cannula.
  • a preferred such container is a septum-sealed vial, wherein the gas-tight closure is crimped on with an overseal (typically of aluminium).
  • the closure is suitable for single or multiple puncturing with a hypodermic needle (e.g. a crimped-on septum seal closure) whilst maintaining sterile integrity.
  • Such containers have the additional advantage that the closure can withstand vacuum if desired (eg. to
  • Preferred multiple dose containers comprise a single bulk vial (e.g. of 10 to 30 cm 3 volume) which contains multiple patient doses, whereby single patient doses can thus be withdrawn into clinical grade syringes at various time intervals during the viable lifetime of the preparation to suit the clinical situation.
  • Pre-filled syringes are designed to contain a single human dose, or "unit dose” and are therefore preferably a disposable or other syringe suitable for clinical use.
  • the pharmaceutical formulations of the present invention preferably have a dosage suitable for a single patient and are provided in a suitable syringe or container, as described above.
  • the pharmaceutical formulations of the invention may be prepared under aseptic manufacture (ie. clean room) conditions to give the desired sterile, non-pyrogenic product. It is preferred that the key components, especially the excipients plus those parts of the apparatus which come into contact with the pharmaceutical formulation (for example, vials) are sterile.
  • the components of the pharmaceutical formulation can be sterilised by methods known in the art, including: sterile filtration, terminal sterilisation using, for example, gamma-irradiation, autoclaving, dry heat or chemical treatment (for example, with ethylene oxide). It is preferred to sterilise some components in advance, so that the minimum number of manipulations needs to be carried out. As a precaution, however, it is preferred to include at least a sterile filtration step as the final step in the preparation of the pharmaceutical formulation.
  • an "effective amount" of a compound of formula (I), (II), (III), (IV), (V), or (VI) or a salt thereof means an amount which is effective for use in in vivo PET imaging or for use in therapy and will vary depending on the exact compound to be administered, the weight of the subject or patient, and other variables as would be apparent to a physician skilled in the art.
  • the fluorine- 18 labeled compounds of this invention may be administered to a subject for PET imaging in amounts sufficient to yield the desired signal, typical radionuclide dosages of 0.01 to 100 mCi, preferably 0.1 to 50 mCi will normally be sufficient per 70kg bodyweight.
  • the alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine compounds I, II, III, IV, V, and VI provided by the present invention may comprise a fluorine- 18 atom in the fluorinated aliphatic moiety -R 1 .
  • such alpha-fluoroalkyl compounds comprising a fluorine- 18 atom are useful as PET imaging agents.
  • the present invention provides a PET imaging agent comprising an alpha-fluoroalkyl tetrabenazine compound having structure I
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical comprising at least one fluorine- 18 atom
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • the present invention provides a PET imaging agent comprising an enantiomerically enriched alpha-fluoroalkyl tetrabenazine compound comprising a principal component enantiomer having structure II
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical comprising at least one fluorine- 18 atom
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • the present invention provides a PET imaging agent comprising an enantiomerically enriched alpha-fluoroalkyl tetrabenazine compound comprising a principal component enantiomer having structure III
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical comprising at least one fluorine- 18 atom
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • the present invention provides a PET imaging agent comprising an enantiomerically enriched alpha-fluoroalkyl tetrabenazine compound having structure I, wherein R 1 is a Cs-C 10 fluoraliphatic radical comprising at least one fluorine- 18 atom, and R 2 and R 3 are methoxy groups.
  • the present invention provides a PET imaging agent comprising an alpha-fluoroalkyl dihydrotetrabenazine compound having structure IV
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical comprising at least one fluorine- 18 atom
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 4 is hydrogen, a C 1 -C 10 aliphatic radical, a C 3 -C 10 cycloaliphatic radical, or a C 3 -C 10 aromatic radical.
  • the present invention provides a PET imaging agent comprising an enantiomerically enriched alpha-fluoroalkyl dihydrotetrabenazine compound comprising a principal component enantiomer having structure V
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical comprising at least one fluorine- 18 atom
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 4 is hydrogen, a C 1 -C 10 aliphatic radical, a C 3 -C 10 cycloaliphatic radical, or a C 3 -C 10 aromatic radical.
  • the present invention provides a PET imaging agent comprising an enantiomerically enriched alpha-fluoroalkyl dihydrotetrabenazine compound comprising a principal component enantiomer having structure VI
  • R 1 is a C 1 -C 10 fluorinated aliphatic radical comprising at least one fluorine- 18 atom
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical
  • R 4 is hydrogen, a C 1 -C 10 aliphatic radical, a C 3 -C 10 cycloaliphatic radical, or a C 3 -C 10 aromatic radical.
  • the present invention provides a PET imaging agent comprising an enantiomerically enriched alpha-fluoroalkyl dihydrotetrabenazine compound having structure IV, wherein R 1 is a C 5 -C 10 fluoraliphatic radical comprising at least one fluorine- 18 atom; and R 2 and R 3 are methoxy groups.
  • PET imaging agent refers to a composition comprising a fluorine- 18 labeled alpha-fluoroalkyl tetrabenazine or dihydrotetrabenazine compound which may be administered to a patient in order to perform a PET scan.
  • the imaging agent is presented to the patient in the form of an aqueous formulation containing a sufficient amount of fluorine- 18 labeled alpha-fluoroalkyl tetrabenazine or dihydrotetrabenazine compound to conduct the PET scan.
  • the amount of fluorine- 18 labeled alpha-fluoroalkyl tetrabenazine or dihydrotetrabenazine compound presented to a patient corresponds to a weight of the fluorine- 18 labeled alpha-fluoroalkyl compound on the order of nanograms.
  • the PET imaging agent typically has a specific activity in a range from about 0.01 to about 10 percent. In one embodiment, the PET imaging agent has a specific activity in a range from about 0.01 to about 5 percent. In another embodiment, the PET imaging agent has a specific activity in a range from about 0.01 to about 1 percent.
  • the aqueous formulation containing the fluorine- 18 alpha-fluoroalkyl tetrabenazine or dihydrotetrabenazine compound is typically administered intravenously and may contain various agents which promote the dispersal of the PET imaging agent in water.
  • the PET imaging agent may be administered to a patient in an aqueous formulation comprising ethanol and the fluorine- 18 labeled alpha-fluoroalkyl compound.
  • the PET imaging agent may be administered to a patient as an aqueous formulation comprising dextrose and the fluorine- 18 labeled alpha-fluoroalkyl compound.
  • the PET imaging agent may be administered to a patient as an aqueous formulation comprising saline and the fluorine- 18 labeled alpha- fluoroalkyl compound.
  • a formulation may optionally contain further excipients as described above, more typically including one or more excipients such as buffers; pharmaceutically acceptable solubilisers (e.g. cyclodextrins or surfactants such as Pluronic, Tween or phospholipids); pharmaceutically acceptable stabilisers or antioxidants (such as ascorbic acid, gentisic acid or p ⁇ ra-aminobenzoic acid.
  • the present invention provides a PET imaging agent comprising both an alpha-fluoroalkyl tetrabenazine compound I and an alpha-fluoroalkyl dihydrotetrabenazine compound IV.
  • the alpha- fluoroalkyl compounds provided by the present invention are believed to possess therapeutic utility in the treatment of diseases such as schizophrenia and Huntington's disease.
  • the present invention provides an alpha-fluoroalkyl tetrabenazine compound having structure I which is useful in treating a pathological condition in a patient.
  • the present invention provides an alpha-fluoroalkyl dihydrotetrabenazine compound having structure IV which is useful in treating a pathological condition in a patient.
  • the present invention provides enantiomerically enriched alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine compounds II, III, V, and VI (and mixtures thereof) which are useful in treating a pathological condition in a patient.
  • the amount of the alpha-fluoroalkyl compound administered to a patient in a given dose is on the order of milligrams.
  • alpha-fluoroalkyl compounds such as alpha- fluoroalkyl compounds falling within the scope of generic structure I, or generic structure IV may under a variety of conditions form salts which are useful as PET imaging agents, probes for the discovery and development of imaging agents, and/or as therapeutic agents.
  • the present invention provides a host of novel and useful alpha-fluoroalkyl compounds and their salts.
  • Suitable salts according to the invention include (i) physiologically acceptable acid addition salts such as those derived from mineral acids, for example hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulphuric acids, and those derived from organic acids, for example tartaric, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, glycollic, gluconic, succinic, methanesulphonic, and para-toluene sulphonic acids; and (ii) physiologically acceptable base salts such as ammonium salts, alkali metal salts (for example those of sodium and potassium), alkaline earth metal salts (for example those of calcium and magnesium), salts with organic bases such as triethanolamine, N-methyl-D-glucamine, piperidine, pyridine, piperazine, and morpholine, and salts with amino acids such as arginine and lysine.
  • physiologically acceptable acid addition salts such as those derived from mineral
  • alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine compounds of the present invention may be prepared by a variety of methods including those provided in the experimental section of this disclosure.
  • the alpha-fluoroalkyl tetrabenazine compound is prepared by reaction of nucleophilic fluoride ion or an electrophilic fluorinating agent with a fluorophilic tetrabenazine compound having structure VII
  • Q is a carbonyl group, a protected carbonyl group, a hydroxy methine group, or a protected hydroxy methine group;
  • R 1 is a C 1 -C 20 aliphatic, C 2 -C 20 cycloaliphatic, or C 2 -C 20 aromatic radical comprising at least one functional group susceptible to reaction with nucleophilic fluoride ion or an electrophilic fluorinating agent;
  • R is hydrogen or a C 1 -C 10 aliphatic radical;
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • access to the alpha- fluoroalkyl dihydrotetrabenazine compounds of the present invention may involve additional chemical transformation (e.g. acetylation) following reaction of compound IV with nucleophilic fluoride ion or an electrophilic fluorinating agent.
  • additional chemical transformation e.g. acetylation
  • R 1 is suitably as further defined below;
  • R 2 and R 3 are each suitably independently selected from hydrogen, C 1-6 alkyl and C 1-6 alkoxy;
  • Q is suitably selected from those groups shown in Table 13 as examples of group Q.
  • the present invention provides a fluorophilic tetrabenazine compound having structure VII.
  • Fluorophilic tetrabenazine compounds having structure VII are illustrated in Table 13 below.
  • the fluorophilic tetrabenazine- and dihydrotetrabenazine compounds which may be used to prepare the compounds of the present invention include compounds which are formally tetrabenazine compounds (i.e., Q is a carbonyl group, for example Entries 13c and 13e of Table 13); compounds which are dihydrotetrabenazine compounds bearing a free hydroxyl group at ring position-2 (i.e., Q is a hydroxy methine group, for example Entry 13b of Table 13); "protected" tetrabenazine compounds (i.e., Q is a protected carbonyl group, for example Q is ethylene ketal group as found in tetrabenazine ketal tosylate 33 of Example 4 herein); or "protected" dihydrotetrabenazine compounds (i.e., Q is a protected hydroxy methine group, for example Q is a
  • protected carbonyl group refers to a carbonyl group equivalent, usually a carbonyl group which has been transformed into a functional group such as a ketal, thioketal, or dithioketal group
  • protected hydroxy methine group refers to a hydroxy methine group equivalent, usually a hydroxy methine group which has been transformed into a functional group such as a tetrahydropyranyl (THP) ether group, a methoxymethyl ether group (MOM group), a methoxyethoxyether group (MEM group), a methylthiomethyl ether group, a benzyl ether group, a p-methoxybenzyl ether group, a pivaloyl ester group (OPiv), or an acetyl ester group (OAc).
  • THP tetrahydropyranyl
  • MOM group methoxymethyl ether group
  • MEM group methoxyethoxyether group
  • Protection agents which may be used to transform a carbonyl group or a hydroxy methine group into a protected carbonyl group or a protected hydroxy methine group are well known in the art, for example protection agents detailed in Protecting Groups In Organic Synthesis by James R. Hanson (Blackwell Science, 1999) and Greene's Protective Groups in Organic Synthesis (Wiley- Interscience, 2006).
  • the present invention provides a fluorophilic compound having structure VII, wherein R 1 is a C 1 -C 20 aliphatic radical, a C 2 -C 20 cycloaliphatic radical, or a C 2 - C 2 o aromatic radical (suitably selected from C ⁇ aUcyl, C 1 _ 6 alkoxy(C 1 _ 6 alkyl), C 1-6 haloalkyl, C 1-6 hydroxyalkyl, and C 1-6 alkylcarbony ⁇ C 1-6 alkyl)) comprising at least one functional group susceptible to reaction with nucleophilic fluoride ion.
  • R 1 is a C 1 -C 20 aliphatic radical, a C 2 -C 20 cycloaliphatic radical, or a C 2 - C 2 o aromatic radical (suitably selected from C ⁇ aUcyl, C 1 _ 6 alkoxy(C 1 _ 6 alkyl), C 1-6 haloalkyl, C 1-6 hydroxyalkyl, and C
  • the functional group susceptible to reaction with nucleophilic fluoride ion is an aromatic sulfonate ester (e.g. tosylate, benzenesulfonate, naphthalenesulfonate), or an aliphatic sulfonate ester (e.g. methane sulfonate, trifluoromethane sulfonate).
  • the functional group susceptible to reaction with nucleophilic fluoride ion is selected from the group consisting of tosylate, mesylate, and trifluoromethane sulfonate groups.
  • the present invention provides a fluorophilic compound having structure VII wherein the group R 1 comprises at least one tosylate group susceptible to reaction with nucleophilic fluoride ion.
  • the tosylate group is an aromatic radical and the group R 1 comprising the tosylate group is also an aromatic radical.
  • the group R 1 comprising the tosylate group is a C 9 aromatic radical which upon displacement with fluoride ion becomes a C 2 fluorinated aliphatic radical.
  • the present invention provides a fluorophilic compound having structure VII wherein the group R 1 comprises at least one mesylate group susceptible to reaction with nucleophilic fluoride ion.
  • the mesylate group is an aliphatic radical and the group R 1 comprising the mesylate group may be an aliphatic, a cycloaliphatic or an aromatic radical depending on the overall structure of the group R 1 .
  • the group R 1 is a cycloaliphatic radical.
  • the group R 1 is an aromatic radical. It is helpful to bear in mind that the definitions of aliphatic, cycloaliphatic and aromatic radicals provided in this disclosure establish a hierarchy in which aliphatic radicals (non-cyclic arrays of atom(s)) must be free of cycloaliphatic groups (a cyclic array of atoms which is not aromatic) and aromatic groups (a cyclic array of atoms which is aromatic), cycloaliphatic radicals must be free of aromatic groups, and aromatic radicals must simply comprise an aromatic group.
  • the present invention provides a fluorophilic compound having structure VII wherein the group R 1 comprises at least one trifluoromethane sulfonate (triflate) group susceptible to reaction with nucleophilic fluoride ion. See for example Entry 13b of Table 13.
  • the present invention provides a fluorophilic compound having structure VII wherein the group R 1 comprises at least one p-nitrobenzoate group susceptible to reaction with nucleophilic fluoride ion. See for example Entry 13c of Table 13.
  • the present invention provides a fluorophilic compound having structure VII wherein the group R 1 comprises at least one methane sulfonate group susceptible to reaction with nucleophilic fluoride ion. See for example Entry 13d of Table 13.
  • the present invention provides a fluorophilic compound having structure VII wherein the group R 1 comprises at least one epoxy group susceptible to reaction with nucleophilic fluoride ion. See for example Entry 13i of Table 13.
  • the present invention provides a fluorophilic compound having structure VII wherein the group R 1 comprises at least one cyclic sulfate group susceptible to reaction with nucleophilic fluoride ion. See for example Entry 131 of Table 13.
  • the present invention provides a fluorophilic compound having structure VII, wherein R 1 is a C 2 -C 20 aliphatic radical comprising at least one functional group susceptible to reaction with an electrophilic fluorinating agent, for example fluorine gas, perchloryl fluoride, mercuric fluoride, and phenyl selenenyl fluoride.
  • an electrophilic fluorinating agent for example fluorine gas, perchloryl fluoride, mercuric fluoride, and phenyl selenenyl fluoride.
  • the functional group susceptible to reaction with an electrophilic fluorinating agent is selected from the group consisting of carbon-carbon double bonds and carbon-carbon triple bonds.
  • Entries 13e, 13f, 13g, 13h and 13k of Table 13 illustrate compounds falling within the scope of generic structure VII which are susceptible to reaction with an electrophilic fluorinating agent. Attention is called to Entry 13k wherein the group R 1 comprises functional groups susceptible to reaction with an electrophilic fluorinating agent (double bond) and to reaction with nucleophilic fluoride ion (tosylate group).
  • Entry 13k of Table 13 also features a thioketal carbonyl protecting group.
  • a thioketal protecting group comprises both an oxygen and a sulfur atom bonded to the "carbonyl carbon" and is distinguished from a dithioketal which comprises two sulfur atoms attached to the "carbonyl carbon".
  • Fluorophilic tetrabenazine compounds VII may be prepared in enantiomerically enriched or racemic forms.
  • a fluorophilic tetrabenazine compound VII may be enriched in the R,R,R- enantiomer shown in Entry 13h of Table 13.
  • a fluorophilic tetrabenazine compound may be enriched in an enantiomer having absolute stereochemistry opposite that of Entry 13d of Table 13, for example the S,S,S-enantiomer of Entry 13f.
  • the present invention provides an enantiomerically enriched fluorophilic compound comprising a principal component enantiomer having structure VIII
  • Q is a carbonyl group, a protected carbonyl group, a hydroxy methine group, or a protected hydroxy methine group;
  • R 1 is a C 1 -C 20 aliphatic, C 2 -C 20 cycloaliphatic, or C 2 -C 20 aromatic radical comprising at least one functional group susceptible to reaction with nucleophilic fluoride ion or an electrophilic fluorinating agent;
  • R is hydrogen or a C 1 -C 10 aliphatic radical;
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • Principal component enantiomers VIII are illustrated by Entries 13b, 13d, 13h, and 13k of Table 13.
  • access to the alpha- fluoroalkyl dihydrotetrabenazine compounds of the present invention may involve additional chemical transformation (e.g. acetylation) following reaction of compound V with nucleophilic fluoride ion or an electrophilic fluorinating agent.
  • the present invention provides an enantiomerically enriched fluorophilic compound comprising a principal component enantiomer having structure IX
  • Q is a carbonyl group, a protected carbonyl group, a hydroxy methine group, or a protected hydroxy methine group;
  • R 1 is a C 1 -C 20 aliphatic, C 2 -C 20 cycloaliphatic, or C 2 -C 20 aromatic radical comprising at least one functional group susceptible to reaction with nucleophilic fluoride ion or an electrophilic fluorinating agent;
  • R 2 is hydrogen or a C 1 -C 10 aliphatic radical;
  • R 3 is hydrogen or a C 1 -C 10 aliphatic radical.
  • Principal component enantiomers IX are illustrated by Entries 13e and 13f of Table 13.
  • access to the alpha- fluoroalkyl dihydrotetrabenazine compounds of the present invention may involve additional chemical transformation (e.g. acetylation) following reaction of compound VI with nucleophilic fluoride ion or an electrophilic fluorinating agent.
  • Co-pending International Patent Application PCT/US2008/065738 discloses methods for the preparation of racemic and enantiomeric ally enriched tetrabenazine compositions which may be used in the preparation of compounds of the present invention.
  • the Examples Section of the present disclosure provides detailed experimental descriptions of the preparation and characterization of fluorophilic tetrabenazine compounds VII and their conversion to alpha-fluoroalkyl tetrabenazine compounds I and alpha-fluoroalkyl dihydrotetrabenazine compounds IV.
  • fluorophilic tetrabenazine compounds VII can be prepared by reacting a nucleophilic alkenyl species with an aldehyde compound having structure X
  • R 3 is hydrogen or a C 1 -C 20 aliphatic radical
  • R 4 is hydrogen or a C 1 -C 20 aliphatic radical
  • P 1 is a protecting group
  • aldehyde compounds X may be prepared from intermediates prepared using methodology described by Sasamoto et al. (Journal of the American Chemical Society 128, 14010-14011, 2006).
  • Sasamoto et al. disclose the preparation of enantiomerically enriched tetrahydroquinoline malonate compounds which may be converted as shown in the present disclosure to aldehyde compound X by selective hydrolysis of one of the ester moieties of the tetrahydroquinoline malonate and decarboxylation followed by reduction of the resultant tetrahydroisoquinoline monoester to aldehyde compound X as depicted in Scheme 1.
  • DM-SEGPHOS 2 mole percent DM-SEGPHOS shown in Scheme 1 represents a chiral catalyst responsible for the enantiomeric enrichment of the product aldehyde X, and further that the use of DM-SEGPHOS of opposite chirality as the chiral catalyst will afford a product aldehyde X enantiomeric ally enriched in the "S" enantiomer (aldehyde compound X having the S configuration at ring position- 12 (See for example Entry 14b of Table 14).
  • Suitable chiral catalysts include those disclosed by Sasamoto et al.
  • racemic aldehyde compound X may be separated into its constituent enantiomers by high performance liquid chromatography (hplc) on a chiral hplc column.
  • enantiomerically enriched compositions include conversion of a racemic alpha-fluoroalkyl compound having structure I compound into an adduct comprising a mixture of diastereomers which are then separated by fractional crystallization.
  • a racemic alpha-fluoroalkyl compound having structure I may be reacted with (-)-tartaric acid to form an adduct (ammonium tartarate salt) of the racemic alpha-fluoroalkyl compound, said adduct comprising a mixture of diastereomeric ammonium tartarate salts which are then separated by fractional crystallization.
  • the dihydroisoquinoline 1 (1.0 eq.) and Boc anhydride (1.5 eq.) were dissolved in CH 2 Cl 2 at room temperature to provide a 1.5 M solution with respect to the dihydroisoquinoline. The mixture was allowed to stir for 30 min. Following the allotted time, the reaction mixture was cooled to 0 °C and then diisopropylmalonate (1.5 eq.) followed by a pre-chilled solution of the Pd catalyst (0.008 eq.) in dichloromethane were added successively to the reaction mixture to provide a final reaction concentration of 0.84 M with respect to the starting dihydroisoquinoline. The reaction mixture was allowed to continue stirring at -2.5 °C for 15 h.
  • the starting material 2 was taken up in isopropanol to provide a 0.2 M solution of 2. To this solution was added IM aqueous NaOH solution bringing the final concentration of the reaction mixture to 0.1M with respect to the malonate 2. The reaction mixture was heated to and maintained 70 °C for 22 min. (timing was started when the temperature of the reaction mixture temp exceeded 65 °C). Following the allotted time the reaction mixture was quickly cooled to 0 °C. The reaction mixture carefully acidified with 2M aqueous HCl and extracted with three portions of dichloromethane. The combined organic extracts dried (Na 2 SO 4 ), filtered and concentrated under reduced pressure.
  • the isolated material was taken up in THF to provide a 0.1 M solution (based on the original quantity of 2 used in the reaction mixture) and triethylamine (1.0 eq) was added to the reaction mixture at room temperature.
  • the reaction mixture was heated to its reflux temperature and maintained at this temperature for 90 min.
  • the reaction mixture was concentrated under reduced pressure, dissolved in a minimal quantity of CH 2 Cl 2 and was immediately purified by column chromatography on SiO 2 (15-40% EtOAc-hexanes; 40%, the eluant was monitored at 284 nm).
  • the product 3 existed as a mixture of rotamers at room temperature and was a colorless foam 79%: [ ⁇ ] 26 o - 82 ( c 0.24, CH 2 Cl 2 ); 1 H NMR (CDCl 3 ) ⁇ 1.19-1.25 (m, 6H), 1.43-1.49 (m, 9H), 2.58-2.69 (m, 2H), 2.70-2.77 (m, 1H), 2.78-2.92 (m, 1H), 3.13-3.43 (m, 1H), 3.81-3.85 (m, 6H), 3.86- 4.01 (m, 1H), 4.91-5.05 (m, 1H), 5.38-5.61 (m, 1H), 6.56-6.61 (m, 1H), 6.64-6.70 (s, 1H); 13 C NMR (CDCl 3 ) ⁇ 21.75, 21.90, 27.93, 28.08, 28.44, 37.53, 38.75, 42.22, 42.81, 51.11, 51.87, 55.92, 56.
  • the combined organic extracts were washed with two portions of 2 M aqueous HCl solution, brine, dried (MgSO 4 ), filtered, and concentrated under reduced pressure.
  • the crude product was subjected purification on SiO 2 (15-35% EtO Ac -hexanes; Elution was observed at 285 nm and 228 nm).
  • the isolated product aldehyde compound 4 was a colorless foam.
  • the mixture was vortexed for about 2 min. to provide a homogeneous, green/grey paste and then stirred under nitrogen for an additional 10 min. after which time anhydrous DMF was added to bring the final reaction concentration to 0.36 M.
  • the reaction mixture was deep green in color and was permitted to continue stirring at room temperature for 14h. Following the allotted time, the reaction mixture was diluted with 1:1 EtOAc-hexanes and an aqueous 0.5 M EDTA solution (pH 9) was added and the entire mixture was allowed to stir for 1.5 h.
  • the aqueous layer was extracted with three portions of EtOAc, dried (MgSO 4 ), filtered, and the filtrate was concentrated under reduced pressure to provide a green oil.
  • the crude material was subjected to column chromatography on SiO 2 (35% EtOAc-hexanes; elution was observed at 285 nm and 228 nm).
  • the product allylic alcohol 6 was a pale yellow oil isolated in 53% yield as a mixture of diastereomers which was taken on to the next step without additional characterization or analysis.
  • the mixture was vortexed for about 2 min. to provide a homogeneous, green/grey paste and then stirred under nitrogen for an additional 10 min. after which time anhydrous DMF was added to bring the final reaction concentration to 0.32 M.
  • the reaction mixture was deep green in color and was permitted to continue stirring at room temperature for 14 h. Following the allotted time, the reaction mixture was diluted with 1 : 1 EtOAc-hexanes and an aqueous 0.5 M EDTA solution (pH 9) was added and the entire mixture was allowed to stir for 1.5 h.
  • the aqueous layer was extracted with three portions of EtOAc, dried (MgSO 4 ), filtered, and the filtrate was concentrated under reduced pressure to provide a green oil.
  • reaction mixture was diluted with 1:1 EtOAc-hexanes and an aqueous 0.5 M EDTA solution (pH 9) was added and the entire mixture was allowed to stir for 1.5 h.
  • aqueous 0.5 M EDTA solution pH 9
  • the aqueous layer was extracted with three portions of EtOAc, dried (MgSO 4 ), filtered, and the filtrate was concentrated under reduced pressure to provide a green oil.
  • the crude material was purified by column chromatography on SiO 2 (10-30% EtOAc-hexanes, elution was observed at 285 nm and 228 nm).
  • the crude material was purified by column chromatography on SiO 2 (10-50% EtOAc-hexanes, elution was observed at 285 nm and 228 nm).
  • the crude material was purified by column chromatography on SiO 2 (10-50% EtOAc-hexanes, elution was observed at 285 nm and 228 nm).
  • First intermediate 12 (1.0 eq) was dissolved in 10% Me 2 S-dichloromethane to provide an 82 mM solution. The solution was cooled to 0 °C and triisopropylsilane (1.1 eq.) followed by
  • the reaction mixture was permitted to stir at 0 °C for 1 h. Following the allotted time the reaction mixture was quenched at 0 °C by the addition of saturated aqueous potassium carbonate solution and concentrated under reduced pressure to remove the majority of the dimethylsulfide. The mixture was extracted with five portions of dichloromethane, and the combined organic extracts were washed with brine, dried (MgSO 4 ), filtered and concentrated under reduced pressure to provide the crude product as a yellow solid. The crude product was recrystallized from 3.5% dimethoxyethane in hexanes.
  • the first intermediate starting material 13 (1.0 eq) was dissolved in 10% Me 2 S- dichloromethane to provide an 26 mM solution. The solution was cooled to 0 °C and triisopropylsilane (1.1 eq.) followed by TFA (precooled to 0 °C) was added to the reaction mixture to provide a final concentration of 13 mM. The reaction mixture was permitted to stir at 0 °C for 1 h. Following the allotted time the reaction mixture was quenched at 0 °C by the addition of saturated aqueous potassium carbonate solution and concentrated under reduced pressure to remove the majority of the dimethylsulfide.
  • the mixture was extracted with five portions of dichloromethane, and the combined organic extracts were washed with brine, dried (MgSO 4 ), filtered and concentrated under reduced pressure to provide an orange oil.
  • the isolated material was immediately subjected to purification by flash chromatography on SiO 2 (20-30% EtOAc-hexanes, elution was observed at 285 nm and 228 nm).
  • the semipure product (existed as a mixture of diastereomers heavily favoring the desired product) was subjected to crystallization from 3.5% dimethoxyethane in hexanes over several days.
  • the starting material 14 (1.0 eq) was dissolved in 10% Me 2 S-dichloromethane to provide a 176 mM solution of the starting material. The solution was cooled to 0 °C and triisopropylsilane (1.1 eq.) followed by TFA (precooled to 0 °C) was added to the reaction mixture to provide a final concentration of 88 mM. The reaction mixture was permitted to stir at 0 °C for 1 h. Following the allotted time the reaction mixture was quenched at 0 °C by the addition of saturated aqueous potassium carbonate solution and concentrated under reduced pressure to remove the majority of the dimethylsulfide.
  • the combined organic extracts were dried (MgSO 4 ), filtered, and concentrated under reduced pressure to provide a yellow oil that was purified by flash chromatography on SiO 2 (1% triethylamine-DCM to 1% triethyamine-5% methanol-94% DCM, 40CV; elution was observed at 284nm and 240 nm).
  • the purified product alpha-fluoroalkyl ketal 21 was obtained as a yellow oil in 60% yield.
  • the isolated material was taken on to the next step without additional characterization.
  • the crude material was purified by semi-preparative HPLC on a Phenomenex Gemini C 18 column 5 ⁇ m, (4.6 x 250 mm; UV @ 284 nm and 240 nm) at a Flow rate of 1.0 niL/min.
  • the following gradient was used: 100% 0.1 mM TEAA buffer pH 7.0 and holding for 3 min. then ramping to 98% MeCN 2 % 0.1 mM TEAA buffer pH 7.0 over 25 min and finally holding at this level for an additional 12 min.
  • the column was maintained at room temperature during the analysis.
  • the minor epimer, 2-epi-24 was converted by a series of steps analogous to Method steps 19 (protection of the hydroxy methine group as a THP ether to provide 2-epi-26), 21 (removal of the t- butyldiphenylsilyl group to provide 2-epi-28), and 23 (reaction of the primary hydroxy group with DAST to provide 2-epi-30); and then removal of the THP ether protecting group in a step analogous to that described in Example 3 to provide the alpha-fluoroalkyl dihydrotetrabenazine 2-epi-32 (See Table 15), a compound identical in structure to compound 32 in all respects save the configuration at ring position-2 which is "S" rather than "R".
  • the intermediate 2-epi-28 was characterized by low resolution mass spectroscopy: LRMS-(ESI+) calcd for (C 24 H 37 NO 5 + H) [M+H] + 448.31, found 448.26.
  • Alpha-fluoroalkyl dihydrotetrabenazine 2-epi-32 was characterized by high resolution mass spectroscopy: HRMS-(ESI+) calcd for (C 21 H 32 FNO 3 + H) [M+H] + 366.24445, found 366.24333.
  • the aqueous layer was extracted with three portions of CH 2 Cl 2 , and the combined organic extracts were dried, (MgSO ⁇ ), filtered, and concentrated under reduced pressure to provide a yellow oil that was immediately subjected to purification by flash chromatography on SiO 2 (1% triethylamine-DCM to 1% triethyamine-5% methanol-94% DCM; elution was observed at 284nm and 240 nm).
  • the aqueous layer was extracted with three portions of CH 2 Cl 2 , and the combined organic extracts were dried, (MgSO ⁇ ), filtered, and concentrated under reduced pressure to provide protected dihydrotetrabenazine compound 26 as a yellow foam that existed as a roughly 1 : 1 mixture of diastereomers the crude product was taken on to the next step without additional purification 99%.
  • the crude material was purified by column chromatography on SiO 2 (1% triethylamine-DCM to 1% triethyamine-10% methanol-89% DCM; elution was observed at 284nm and 240 nm).
  • the product alpha-hydroxyalkyl protected dihydrotetrabenazine compound 27 eluted late in the run as a broad peak.
  • the crude material was purified by column chromatography on SiO 2 (1% triethylamine-DCM to 1% triethyamine-10% methanol-89% DCM; elution was observed at 284nm and 240 nm). The product eluted late in the run as a broad peak.
  • the combined organic extracts were dried (MgSO 4 ), filtered, and concentrated under reduced pressure to provide an orange oil that was purified by flash chromatography on SiO 2 (1% triethylamine-DCM to 1% triethyamine-10% methanol-89% DCM, 40CV; elution was observed at 284nm and 240 nm).
  • the desired product eluted as a broad peak, late in the run.
  • the product alpha-fluoroalkyl protected dihydrotetrabenazine compound 30 was an oil that existed as a 1:1 mixture of diastereomers 46%. The isolated material was taken on to the next step without additional characterization or analysis.
  • the reaction mixture was permitted to stir for 1.5 h at room temperature.
  • the solvent was removed under reduced pressure, and the residue was dried under high vacuum for one hour.
  • the residue was treated with aqueous potassium carbonate solution and extracted with three portions of dichloromethane.
  • the starting material was dissolved in 0.1 M HCl in MeOH to provide a 26 mM solution of the starting material 30.
  • the reaction mixture was permitted to stir for 1.5 h at room temperature.
  • the solvent was removed under reduced pressure, and the residue was dried under high vacuum for one hour.
  • the residue was treated with aqueous potassium carbonate solution and extracted with three portions of dichloromethane.
  • An [ rl8 T F]KF solution (about 1 mL) is transferred from a vial containing the F- 18 in water, through an anion exchange resin (Chromafix 30-PS-HCO3, ABX).
  • the immobilized F-18 fluroide ion is then transferred too a reaction vial using about 1 mL of a 4:1 solution of acetonitrile and water with potassium carbonate (about 2 mg), and Kryptofix 221 (about 16 mg).
  • the vial is heated at 40°C under a stream of nitrogen and partial vacuum to effect the azeotropic removal of water. Additional dry acetonitrile (1 mL) is added and evaporated. This azeotropic drying protocol is repeated three times.
  • a mixture of dimethyl formamide and acetonitrile (about 1 mL) containing fluorophilic protected TBZ tosylate 33 (about 2 mg) is added and the vial is sealed.
  • the reaction mixture is stirred and heated at 100°C for 10 minutes and then is cooled to room temperature.
  • the product mixture comprising the starting tosylate 33 and the product F-18 alpha-fluoroalkyl protected tetrabenazine is diluted with water (10 mL) and applied to a Sep-Pak cartridge. The cartridge is then washed with water (3x) to remove unreacted fluoride ion and other water soluble components of the product mixture.
  • the radiolabled alpha-fluoroalkyl protected tetrabenazine compound and starting tosylate 33 are then eluted from the cartridge with acetonitrile. Most of the acetonitrile is then evaporated and the residue is dissolved in aqueous methanol containing hydrochloric acid (HCl) and heated at 60°C. The mixture is again diluted to about 2 mL with water and subjected to preparative reverse phase HPLC to afford the purified tracer in a mixture of acetonitrile and water. The fractions containing the desired tracer are diluted 5-fold with distilled, deionized water and applied to a Sep-Pak cartridge.
  • HCl hydrochloric acid
  • the cartridge is washed with water, then purged with nitrogen for 3 minutes.
  • Compound 35 is isolated by eluting from the SepPak using ethanol or dimethylsulfoxide.
  • An aqueous formulation comprising PET imaging agent 35 is generated by removing the ethanol under a stream of nitrogen and/or adding an appropriate amount of saline..
  • An [ 18 F]KF solution (about 1 mL) is transferred from a vial containing the F- 18 in water, through an anion exchange resin (Chromafix 30-PS-HCO3, ABX).
  • the immobilized F-18 fluroide ion is then transferred too a reaction vial using about 1 mL of a 4:1 solution of acetonitrile and water with potassium carbonate (about 2 mg), and Kryptofix 221 (about 16 mg).
  • the vial is heated at 40°C under a stream of nitrogen and partial vacuum to effect the azeotropic removal of water. Additional dry acetonitrile (1 mL) is added and evaporated. This azeotropic drying protocol is repeated three times.
  • a mixture of dimethyl formamide and acetonitrile (about 1 mL) containing fluorophilic protected DTBZ tosylate 34 (about 2 mg) is added and the vial is sealed.
  • the reaction mixture is stirred and heated at 100°C for 10 minutes and then is cooled to room temperature.
  • the product mixture comprising the starting tosylate 34 and the intermediate F-18 alpha- fluoroalkyl protected dihydrotetrabenazine is diluted with water (10 mL) and applied to a Sep-Pak cartridge. The cartridge is then washed with water (3x) to remove unreacted fluoride ion and other water soluble components of the product mixture.
  • the radiolabled alpha-fluoroalkyl intermediate and starting tosylate 34 are then eluted from the cartridge with acetonitrile and treated with water containing DOWEX strongly acidic cation exchangeresin at 65 °C for 10 minutes
  • the reaction mixture is then filtered and diluted to about 2 mL with water and subjected to preparative reverse phase HPLC to afford the purified tracer in a mixture of acetonitrile and water.
  • the fractions containing the desired tracer are diluted 5- fold with distilled, deionized water and applied to a Sep-Pak cartridge. The cartridge is washed with water, then purged with nitrogen for 3 minutes.
  • Compound 36 is isolated by eluting from the SepPak using ethanol or dimethylsulfoxide.
  • An aqueous formulation comprising PET imaging agent 36 is generated by removing the ethanol under a stream of nitrogen and/or adding an appropriate amount of saline.
  • An [ 18 F]KF solution (about 1 mL) is transferred from a vial containing the F- 18 in water, through an anion exchange resin (Chromafix 30-PS-HCO3, ABX).
  • the immobilized F-18 fluroide ion is then transferred too a reaction vial using about 1 mL of a 4:1 solution of acetonitrile and water with potassium carbonate (about 2 mg), and Kryptofix 221 (about 16 mg).
  • the vial is heated at 40°C under a stream of nitrogen and partial vacuum to effect the azeotropic removal of water. Additional dry acetonitrile (1 mL) is added and evaporated. This azeotropic drying protocol is repeated three times.
  • a mixture of dimethyl formamide and acetonitrile (about 1 mL) containing fluorophilic tosylate 34 (about 2 mg) is added and the vial is sealed.
  • the reaction mixture is stirred and heated at 100°C for 10 minutes and then is cooled to room temperature.
  • the product mixture comprising the starting tosylate 34 and the product F-18 alpha- fluoroalkyl protected dihydrotetrabenazine intermediate is concentrated under a stream of nitrogen and the residue is dissolved in ethanol containing HCl and the mixture is warmed briefly to effect removal of the THP protecting group.
  • the mixture is again diluted to about 2 mL with water and subjected to preparative reverse phase HPLC to afford the purified tracer in a mixture of acetonitrile and water.
  • the fractions containing the desired tracer are diluted 5-fold with distilled, deionized water and applied to a Sep-Pak cartridge. The cartridge is washed with water, then purged with nitrogen for 3 minutes.
  • Compound 36 is isolated by eluting from the SepPak using ethanol or dimethylsulfoxide.
  • An aqueous formulation comprising PET imaging agent 36 is generated by removing the ethanol under a stream of nitrogen and/or adding an appropriate amount of saline.
  • VMAT-2 binding affinities were measured for alpha-fluoroalkyl dihydrotetrabenazine compounds 31, 32, and 2-epi-32 provided by the present invention.
  • VMAT-2 binding affinity measurements were carried out by Novascreen Biosciences Corporation (Hanover, Maryland, USA) using protocol Cat. No. 100-0751.
  • Novascreen, Inc. is a commercial provider of biological assays for the pharmaceutical industry. Binding affinity data are presented in Table 15 and illustrate very high binding affinity for the alpha-fluoroalkyl compounds of the present invention relative to a DTBZ control (Comparative Example 1).
  • alpha-fluoroalkyl compounds 31, 32 and 2-epi-32 reveal an unexpected tolerance of fluoroalkyl substitution at ring position-3, a structural change relative to TBZ and DTBZ which combines a change in the size and lipophilicity of the group at ring position-3 with the uncertainty which arises whenever a hydrogen in a biologically active molecule is replaced by fluorine.
  • the binding constants Ki expressed in nanomolar (nM) concentration units indicate a very high affinity of the alpha-fluoroalkyl compounds of the present invention for the VMAT-2 biomarker.
  • aqueous and organic layers are partitioned and separated, and the aqueous layer is extracted with two additional 1 mL portions of dichloromethane.
  • the combined organic extracts are washed with 3 mL of brine, dried (MgSO 4 ), filtered, and concentrated under reduced pressure to provide crude alpha- fluoroalkyl dihydrotetrabenazine acetate 40 that may be purified by preparative reversed phase HPLC.
  • reaction mixture is then quenched by the addition of 1 mL of saturated aqueous ammonium chloride solution and then diluted with an additional 750 ⁇ L of dichloromethane.
  • the aqueous and organic layers are partitioned and separated, and the aqueous layer is extracted with two additional 1 mL portions of dichloromethane.
  • the combined organic extracts are washed with 3 mL of brine, dried (MgSO 4 ), filtered, and concentrated under reduced pressure to provide crude alpha- fluoroalkyl dihydrotetrabenazine isobutyrate 41 that may be purified by preparative reversed phase HPLC.
  • reaction mixture is then quenched by the addition of 1 mL of saturated aqueous ammonium chloride solution and then diluted with an additional 750 ⁇ L of dichloromethane.
  • the aqueous and organic layers are partitioned and separated, and the aqueous layer is extracted with two additional 1 mL portions of dichloromethane.
  • the combined organic extracts are washed with 3 mL of brine, dried (MgSO 4 ), filtered, and concentrated under reduced pressure to provide crude alpha- fluoroalkyl dihydrotetrabenazine N-benzylcarbamate 42 that may be purified by preparative reversed phase HPLC.
  • a suspension of triphosgene (3.9 mg, 13.2 ⁇ mol) in 150 ⁇ L of carbon tetrachloride and 2.6 ⁇ L (1.2 equiv., 32.4 ⁇ mol) of anhydrous pyridine is added to a stirred solution of 10 mg (27 ⁇ mol) of alpha- fluoroalkyl dyhydrotetrabenazine compound 32 in 150 ⁇ L of carbon tetrachloride.
  • the resulting solution is stirred in a sealed vessel at 55-60 °C for 6 h. Following the allotted time the reaction mixture is cooled to room temperature, and the mixture is diluted with 250 ⁇ L of dichloromethane.
  • the mixture is washed with two 200 ⁇ L portions of water and one 200 ⁇ L portion of brine, dried (Na 2 SO 4 ), and concentrated under reduced pressure to provide the crude chloroformate.
  • the crude material is dissolved in 60 ⁇ L of THF and is cooled in an ice bath. To this solution is added 60 ⁇ L of a 50% aqueous ammonia solution with vigorous stirring. The reaction mixture is allowed to continue stirring, slowly warming to room temperature over 14 h. Excess ammonia is removed under a stream of dry nitrogen. The residue is taken up in 2 mL of dichloromethane and washed with 1 mL of brine.
  • the organic layer is collected, and the aqueous layer is washed with an additional 1 mL portion of dichloromethane.
  • the organic extracts are, dried (Na 2 SO 4 ), and concentrated under reduced pressure to provide crude alpha-fluoroalkyl dihydrotetrabenazine carbamate 43 that may be purified by preparative reversed phase HPLC.
  • a mixture of dimethyl formamide and acetonitrile (about 1 mL) containing fluorophilic acetate-protected DTBZ tosylate 44 (2 mg) is added and the vial is sealed.
  • the reaction mixture is stirred and heated at 100°C for 10 minutes and then is cooled to room temperature.
  • the product mixture comprising the starting tosylate 44 and the intermediate F- 18 alpha- fluoroalkyl protected dihydrotetrabenazine is diluted with water (10 mL) and applied to a Sep-Pak cartridge. The cartridge is then washed with water (3x) to remove unreacted fluoride ion and other water soluble components of the product mixture.
  • the radiolabled PET imaging agent 45 and starting tosylate 44 are then eluted from the cartridge with acetonitrile. Most of the acetonitrile is then evaporated and the residue is dissolved in acetonitrile, filtered and subjected to preparative reverse phase HPLC to afford an aqueous formulation comprising PET imaging agent 45.
  • Tosylate 44 may be prepared from compound dihydrotetrabenazine compound 23 by acetylation of the free hydroxy group at ring position-2 followed by deprotection of the t-butyldiphenylsilyl (TBDPS) group and tosylation of the resultant primary alcohol.
  • Example 14 (2R,3R,11bR)-3-(4-hvdroxy-2,2-dimethylbutyl)-9,10-dimethoxy-2,3,4,6,7,l lb- hexahvdro- 1H-pyrido[2,1-a]isoquinolin-2-ol.
  • the starting material (54 mg, 90 ⁇ mol) was dissolved in 2.0 mL of 0.5M TBAF in T ⁇ F.
  • the reaction mixture was stirred at room temperature for 3 h. Following the allotted time, the reaction mixture was quenched by the addition of brine and extracted with dichloromethane. The organic extracts were dried, concentrated under reduced pressure, and then immediately purified by flash chromatography on SiO 2 . (12 g column;(both the dichloromethane and the methanol in this procedure were spiked with 0.1% triethylamine) CH 2 Cl 2 , 2 CV; 0-5% MeOH-CH 2 Cl 2 , 14CV; 5% MeOH- CH 2 Cl 2 , 4 CV elution was observed at 284nm and 236).
  • the organic extracts were dried, concentrated under reduced pressure, and then immediately purified by flash chromatography on SiO 2 (12 g column;(both the dichloromethane and the methanol in this procedure were spiked with 0.1% triethylamine) CH 2 Cl 2 , 2 CV; 0-5% MeOH- CH 2 Cl 2 , 14CV; 5% MeOH- CH 2 Cl 2 , 4 CV elution was observed at 284nm and 236).
  • the isolated product was a pale yellow oil (25 mg, 47 ⁇ mol, 53%) that was analyzed by LCMS prior to being taken up in MeCN and frozen at -80 °C until it could be used for radiofluorination with 18 F.
  • [ 18 F]KF (4OmCi mL- 1 (1480 MBq mL -1 ) in purified water) was obtained from either IBA Molecular (Albany, NY) or PETNET Solutions (Albany, NY) and used as received.
  • the reaction vessel was repressurized with N 2 and the azeotropic drydown repeated once with an additional 1.5mL of acetonitrile.
  • the dried solid was re-suspended with 0.5mL of acetonitrile and allowed to stir for several minutes prior to removing an aliquot.
  • the HPLC fraction containing the product was diluted 5:1 with distilled, deionized H 2 O and subsequently immobilized on a tC18 Plus Sep Pak (Waters).
  • the mobile phase was eluted and the SepPak flushed first with 5 mL of distilled, deionized H 2 O then 30 mL of air.
  • [ 18 F]MR3068 was isolated in a minimal amount of ethanol or DMSO by first eluting the void volume (approx. 0.5mL) followed by collecting 250 to 300 ⁇ L of eluent in a separate flask.
  • RP-HPLC analysis was performed on the isolated product in order to establish radiochemical and chemical purity.
  • Analytical HPLC conditions Analysis performed on an HP Agilent 1100 with a G1311A QuatPump, G1313A autoinjector with lOO ⁇ L syringe and 2.OmL seat capillary, Phenomenex Monolithic C18 column (4.6mmxl00mm), G1316A column heater, G1315A DAD and Ramon Star - GABI gamma-detector.
  • Gradient elution 0 min. 0%B, 4 min. 20%B, lOmin. 80%B, 10.5 min. 100%B, 12 min. 100%B, 13 min. 0%B, 16 min. 0%B. T R ⁇ 6.9 min.
  • Analogue Ratemeter attached to a solid-state SiPIN photodiode gamma detector. Gradient elution: 0 min. 0%B, 0.75 min. 0%B, 1 min. 20%B, 17.5 min. 70%B, 17.75 min. 100%B,
  • the word "comprises” and its grammatical variants logically also subtend and include phrases of varying and differing extent such as for example, but not limited thereto, “consisting essentially of” and “consisting of.” Where necessary, ranges have been supplied, those ranges are inclusive of all sub-ranges there between. It is to be expected that variations in these ranges will suggest themselves to a practitioner having ordinary skill in the art and where not already dedicated to the public, those variations should where possible be construed to be covered by the appended claims. It is also anticipated that advances in science and technology will make equivalents and substitutions possible that are not now contemplated by reason of the imprecision of language and these variations should also be construed where possible to be covered by the appended claims.
EP08854913A 2007-11-29 2008-11-25 Alpha-fluoralkyltetrabenazine und dihydrotetrabenazine als bilddarstellende mittel und sonden Ceased EP2217599A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20130155403 EP2594568A1 (de) 2007-11-29 2008-11-25 Alpha-fluoralkyltetrabenazine und Dihydrotetrabenazine als Bilddarstellende Mittel und Sonden

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/947,215 US7902364B2 (en) 2007-11-29 2007-11-29 Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US11/947,275 US7910738B2 (en) 2007-11-29 2007-11-29 Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US12/174,167 US8053578B2 (en) 2007-11-29 2008-07-16 Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
PCT/US2008/084601 WO2009070552A1 (en) 2007-11-29 2008-11-25 Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes

Publications (1)

Publication Number Publication Date
EP2217599A1 true EP2217599A1 (de) 2010-08-18

Family

ID=40297912

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20130155403 Withdrawn EP2594568A1 (de) 2007-11-29 2008-11-25 Alpha-fluoralkyltetrabenazine und Dihydrotetrabenazine als Bilddarstellende Mittel und Sonden
EP08854913A Ceased EP2217599A1 (de) 2007-11-29 2008-11-25 Alpha-fluoralkyltetrabenazine und dihydrotetrabenazine als bilddarstellende mittel und sonden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20130155403 Withdrawn EP2594568A1 (de) 2007-11-29 2008-11-25 Alpha-fluoralkyltetrabenazine und Dihydrotetrabenazine als Bilddarstellende Mittel und Sonden

Country Status (5)

Country Link
US (1) US8053578B2 (de)
EP (2) EP2594568A1 (de)
JP (1) JP2011505363A (de)
CN (1) CN101878213B (de)
WO (1) WO2009070552A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP2758041B1 (de) * 2011-09-20 2021-01-13 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung
BR112015005894B1 (pt) 2012-09-18 2022-03-29 Auspex Pharmaceuticals, Inc Composto, composição farmacêutica, método para tratar um distúrbio mediado por vmat2 e formulação farmacêutica de liberação prolongada
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EP2951178A4 (de) * 2013-01-31 2016-07-06 Auspex Pharmaceuticals Inc Vmat2-benzochinolonhemmer
US20160207917A1 (en) * 2013-09-27 2016-07-21 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
WO2015077521A1 (en) * 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3424504A1 (de) 2013-12-03 2019-01-09 Auspex Pharmaceuticals, Inc. Verfahren zur herstellung von benzochinolinverbindungen
MX2016009817A (es) * 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
IL305352A (en) 2015-03-06 2023-10-01 Auspex Pharmaceuticals Inc Methods for treating abnormal movement disorders
IL305054A (en) 2021-03-22 2023-10-01 Neurocrine Biosciences Inc VMAT2 inhibitors and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) 1958-07-15 Method for preparing same
DE1068261B (de) * 1959-11-05 F. Hoffmann-La Roche £v Co. Aktiengesellschaft, Basel (Schweiz) Verfahren zur Herstellung von substituierten 2-Oxobenzo-chinollizinen
HU175890B (en) 1977-06-15 1980-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing new 1,2,3,4,6,7-hexahydro-11-b-alpha-benzo-square bracket-a-square brecket closed-quinolyzine derivatives
US5278308A (en) 1992-02-28 1994-01-11 The Trustees Of The University Of Pennsylvania Iodine derivatives of tetrabenazine
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
JP5437630B2 (ja) 2005-06-29 2014-03-12 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク １型糖尿病における膵臓内分泌部及びβ細胞集団を撮像するためのＤＴＢＺの使用
US20110257220A1 (en) 2005-08-06 2011-10-20 Cambridge Laboratories (Ireland) Limited 3,11 b-cis-Dihydrotetrabenazine for the Treatment of Schizophrenia and Other Psychoses
KR101429302B1 (ko) 2006-05-02 2014-08-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 방사성 표지된 디히드로테트라베나진 유도체 및 조영제로서의 이의 용도
US7897768B2 (en) 2007-06-08 2011-03-01 General Electric Company Method for making tetrabenazine compounds
US7902364B2 (en) * 2007-11-29 2011-03-08 General Electric Company Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009070552A1 *

Also Published As

Publication number Publication date
CN101878213B (zh) 2013-05-29
CN101878213A (zh) 2010-11-03
WO2009070552A1 (en) 2009-06-04
US8053578B2 (en) 2011-11-08
US20090142276A1 (en) 2009-06-04
EP2594568A1 (de) 2013-05-22
JP2011505363A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
EP2217599A1 (de) Alpha-fluoralkyltetrabenazine und dihydrotetrabenazine als bilddarstellende mittel und sonden
US10857247B2 (en) Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
US7902364B2 (en) Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
US7919622B2 (en) Intermediates for fluorinated tetrabenazine carbinol compounds imaging agents and probes
EP2220085B1 (de) Fluoralkyltetrabenazincarbinolverbindungen als bilddarstellende mittel und sonden
US20110009419A1 (en) Enantiomers of 2'-Fluoralkyl-6-nitroquipazine as Serotonin Transporter Positron Emission Tomography Imaging Agents and Antidepressant Therapeutics
US7910738B2 (en) Intermediates for alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes
JP2013507345A (ja) インビボイメージング剤としてのフルマゼニルの［１８ｆ］標識類似体
US7897769B2 (en) Intermediates for fluorinated dihydrotetrabenazine ether imaging agents and probes
US9186424B2 (en) Aryloxyanilide imaging agents
US8013161B1 (en) Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
US7897770B2 (en) Fluorinated dihydrotetrabenazine ether imaging agents and probes
JP5663309B2 (ja) フッ素化ジヒドロテトラベナジンエーテルイメージング剤及びプローブ
JP2012509887A (ja) イメージングリガンド
EP2247316B1 (de) Bildgebung des zentralen nervensystems
EP3835293A1 (de) Bildgebende monoaminoxidase-b-sonde

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DINN, SEAN RICHARD

Inventor name: AMARASINGHE, KANDE KANKANANAMALAGE DAYARATHNA

Inventor name: JOHNSON, BRUCE FLETCHER

Inventor name: RISHEL, MICHAEL JAMES

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20110223

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130215